Want to see FENC full AI Analyst Report?

Fennec Pharmaceuticals (FENC) Price & Analysis

259 Followers

FENC Stock Chart & Stats

$9.94

$0.13(1.31%)

At close: Jul 29 4:00 PM EDT

$9.94

$0.13(1.31%)

Day’s Range― - ―

52-Week Range$5.65 - $13.25

Previous Close$6.08

Volume6.00

Average Volume (3M)227.27K

Market Cap

$398.01M

Enterprise Value$350.37

Total Cash (Recent Filing)$41.25M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Nov 05, 2026

EPS Estimate

0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding35,067,158

10 Day Avg. Volume160,837

30 Day Avg. Volume227,270

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)6.28

Price to Sales (P/S)4.93

P/FCF Ratio-17.64

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$18.00

Price Target Upside81.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)0.29

Revenue Forecast (FY)$72.73M

Bulls Say, Bears Say

Bulls Say

PEDMARK Commercial GrowthSustained sales growth and rising infusions, enrollments and active patients indicate expanding PEDMARK adoption. Broader prescriber coverage and stronger site penetration can support durable revenue growth as commercialization matures.

High-margin Product EconomicsThe exceptionally high gross margin provides substantial contribution potential from incremental PEDMARK sales. This creates operating leverage as commercial scale improves, although the company still needs disciplined spending to convert gross profit into durable earnings.

Debt-free Balance SheetA debt-free structure and rebuilt positive equity reduce financing risk and preserve flexibility for commercialization and evidence generation. The cash position, together with projected PEDMARK revenue, supports the current operating plan without stated dependence on debt funding.

Bears Say

Negative Cash GenerationDespite improving from 2025, the business is not yet consistently self-funding. Continued negative and volatile cash flow could constrain investment or require external financing if PEDMARK growth, collections or operating leverage fall short.

Profitability Remains UnprovenPositive adjusted EBITDA in Q2 is encouraging, but GAAP profitability has not been consistent and commercial expansion is increasing SG&A. The company must sustain revenue growth and control spending before earnings quality can be considered durable.

Product And Indication ConcentrationPEDMARK is the core commercial product and sales are concentrated in three tumor types, increasing exposure to changes in treatment patterns or adoption. Diversification depends on clinical evidence, guideline upgrades and possible label expansion that remain uncertain.

Fennec Pharmaceuticals News

Fennec price target raised to $16 from $13 at Wedbush

Wedbush raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps an Outperform rating...

5d ago

FENC

Fennec price target raised to $18 from $16 at B. Riley

B. Riley raised the firm’s price target on Fennec (FENC) to $18 from $16 and keeps a Buy...

5d ago

FENC

Fennec reports Q2 EPS 5c, consensus 2c

Reports Q2 revenue $17.87M, consensus $16.12M. “Our second quarter reflects another period of strong execution across the business,...

11d ago

FENC

FENC Upcoming Earnings Report: What to Expect?

Fennec Pharmaceuticals (FENC) is scheduled to report 2nd quarter earnings on 08/11/2026, before the market opens. Regarding Q2...

13d ago

FENC

Fennec Shareholders Approve Governance, Compensation and Equity Plans

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. On June 10, 2026, Fennec Pharmaceuticals Inc. held its...

2M ago

FENC

Fennec Showcases New PEDMARK Data at ASCO 2026

An announcement from Fennec Pharmaceuticals ( ($TSE:FRX) ) is now available. On May 21, 2026, Fennec Pharmaceuticals announced...

3M ago

FENC

Fennec price target raised to $16 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps a Buy...

3M ago

FENC

Fennec Pharmaceuticals Earnings Call Signals Robust Growth

Fennec Pharmaceuticals (($TSE:FRX)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

FENC

Fennec reports Q1 EPS 1c, consensus (2c)

Reports Q1 revenue $15.1M, consensus $13.84M. “We are encouraged by our continued quarter-over-quarter growth and strong start to...

3M ago

FENC

Fennec Showcases New PEDMARK Data at 2026 ASCO

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an update. On April 21, 2026, Fennec Pharmaceuticals announced that four...

4M ago

FENC

Buy Rating on PEDMARK Undervalues Global Expansion and Pipeline Upside, Supporting $13 Target Price

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals, retaining the price target of...

5M ago

FENC

Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers

An update from Fennec Pharmaceuticals ( ($TSE:FRX) ) is now available. Fennec Pharmaceuticals has announced that the University...

5M ago

FENC

Fennec Pharmaceuticals: Buy Rating Reaffirmed on Accelerating PEDMARK Adoption and Multi-Region Growth Catalysts Through 2027

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals, retaining the price target of...

5M ago

FENC

Fennec Pharmaceuticals Signals Costly Push Toward Growth

Fennec Pharmaceuticals (($TSE:FRX)) has held its Q4 earnings call. Read on for the main highlights of the call....

5M ago

FENC

FENC FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?

Fennec Pharmaceuticals lowest stock price was $5.65 and its highest was $13.25 in the past 12 months.

What is Fennec Pharmaceuticals’s market cap?

Fennec Pharmaceuticals’s market cap is $398.01M.

When is Fennec Pharmaceuticals’s upcoming earnings report date?

Fennec Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 75 days.

How were Fennec Pharmaceuticals’s earnings last quarter?

Fennec Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03.

Is Fennec Pharmaceuticals overvalued?

According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fennec Pharmaceuticals pay dividends?

Fennec Pharmaceuticals does not currently pay dividends.

What is Fennec Pharmaceuticals’s EPS estimate?

Fennec Pharmaceuticals’s EPS estimate is 0.1.

How many shares outstanding does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals has 35,067,158 shares outstanding.

What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?

Fennec Pharmaceuticals reported an EPS of $0.05 in its last earnings report, beating expectations of $0.02. Following the earnings report the stock price went up 16.819%.

Which hedge fund is a major shareholder of Fennec Pharmaceuticals?

Currently, no hedge funds are holding shares in FENC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fennec Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

68.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals (FENC) Earnings & Revenues

Historic Earnings Reports

FENC Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong commercial and clinical momentum: double-digit and sequential revenue growth (+78% YoY in Q2), return to positive adjusted EBITDA, record operational metrics in July, expanded commercial reach and multiple ISTs with notable forthcoming data (SIOP oral presentation). These positives are tempered by higher SG&A and marketing-driven OpEx, short-term cash timing volatility, reliance on a concentrated set of tumor types for the majority of sales, and the need for additional clinical data to drive guideline upgrades and label expansion. Management is bullish on continued growth but remains conservative on formal revenue guidance until further traction and data maturity are achieved.View all FENC earnings summaries

FENC Stock 12 Month Forecast

Average Price Target

$18.00

▲(81.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.57,10.372307692307693,11.174615384615384,11.976923076923077,12.77923076923077,13.581538461538461,14.383846153846154,15.186153846153847,15.98846153846154,16.79076923076923,17.59307692307692,18.395384615384614,19.197692307692307,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.57,10.218461538461538,10.866923076923078,11.515384615384615,12.163846153846155,12.812307692307693,13.46076923076923,14.10923076923077,14.757692307692308,15.406153846153845,16.054615384615385,16.70307692307692,17.35153846153846,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.57,10.064615384615385,10.55923076923077,11.053846153846154,11.548461538461538,12.043076923076923,12.537692307692307,13.032307692307693,13.526923076923076,14.021538461538462,14.516153846153845,15.010769230769231,15.505384615384616,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.59,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.34,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >